Ultragenyx Pharmaceutical has dosed the first participant in Aurora, a study evaluating GTX-102 (apazunersen) for angelman ...
When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...
About AIC468 AIC468 is an antisense oligonucleotide therapy designed to treat BK virus reactivation in kidney transplant patients, a condition that can pose a significant health risk. The candidate ...
WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the ...
An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome. This breakthrough was possible because of the novel findings, also presented ...
Randomized Cross-Over Trial of Progenitor-Cell Mobilization: High-Dose Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor (G-CSF) Versus Granulocyte-Macrophage Colony-Stimulating Factor Plus ...
Clinical Trials Arena on MSN
Spinogenix’s ALS hopeful to advance to registrational trial
"Spinogenix’s ALS hopeful to advance to registrational trial" was originally created and published by Clinical Trials Arena, ...
Please provide your email address to receive an email when new articles are posted on . Phase 1b trial of BII080 demonstrated dose-dependent and sustained reduction of tau protein in CSF, as well as ...
An antisense therapy developed by Joel D. Richter, PhD, Sneha Shah, PhD, and Jonathan K. Watts, PhD, at UMass Chan Medical School and Elizabeth Berry-Kravis, MD, PhD, at RUSH University Medical Center ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback